Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma

Expert Review of Hematology

Volumn 10, Issue 9, 2017, Pages 757-760

  Winsett, Frank T ^a   Lewis, Daniel J ^b,c   Duvic, Madeleine ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b Baylor College of Medicine   (United States)

^c University of Texas Health Science Center at Houston   (United States)

Author keywords

Adult T cell leukemia lymphoma; CC Chemokine receptor 4; Cutaneous T cell lymphoma; Human T lymphotropic virus type 1; Peripheral T cell lymphoma

Indexed keywords

MOGAMULIZUMAB; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CCR4; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CHILL; COLITIS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFUSION RELATED REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PSORIASIS VULGARIS; RASH; T CELL LEUKEMIA; ANTAGONISTS AND INHIBITORS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; IMMUNOLOGY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MORTALITY; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; RECEPTORS, CCR4; RECURRENCE; TREATMENT OUTCOME;

EID: 85028912573     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1080/17474086.2017.1361819     Document Type: Article

References (26)

1. Yoshida M, Miyoshi I, Hinuma Y., Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79(6):2031–2035.
2. Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia:a review of epidemiological evidence. Front Microbiol. 2012;3:322.
3. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers:a nationwide prospective study in Japan. Blood. 2010;116(8):1211–1219.
4. Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol. 2002;76:240–245.
5. Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60(12):1373–1377.
6. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 2005;24(39):6047–6057.
7. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010 Sep 20;28(27):4177–4183.
8. Ohshima K, Karube K, Kowano R, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression:analysis of prognosis. Int J Oncol. 2004;25(3):605–613.
9. Sekine M, Kubuki Y, Kameda T, et al. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. Eur J Haematol. 2017;98:501–507.
10. Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific moecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res. 2004;10(22):7529–7539.
11. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–3473.
12. Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulator T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2015;21(2):274–285.
13. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–1598.• Phase I study of mogamulizumab in ATL.
14. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma:a multicenter phase II study. J Clin Oncol. 2012;30(8):837–842.•• Phase II study of mogamulizumab in ATL conducted in Japan.
15. Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma:a randomized phase II study. Br J Haematol. 2015;169(5):672–682.•• Phase II study comparing mogamulizumab in addition to multidrug chemotherapy alone in the treatment of aggressive ATL.
16. Phillips AA, Fields P, Hermine O, et al. A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator’s choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL). J Clin Oncol. 2016; 34(suppl; abstr 7501)•• Preliminary results of a large phase II trial comparing mogamulizumab to an investigator’s choice (Pralatrexate, Dihydroxyacetone phosphate, or Gemcitabine with oxaliplatin) for efficacy in relapsed/refractory ATL.
17. Duvic M, Pinter-Brown L, Foss F, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–1889.• Large phase I/II study of mogamulizumab in relapsed/refractory CTCL.
18. Ureshino H, Shindo T, Nishikawa H, et al. Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016 [cited 2016 May23];4:644–649.
19. Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–1163.
20. Ishitsuka K, Murahashi M, Katsuya H, et al. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. Int J Hematol. 2015;102(4):493–497.
21. Morichika K, Tomoyose T, Hanashiro T, et al. Recurrence of psoriasis vulgaris accompanied by treatment with C-C chemokine receptor type 4 (CCR4) antibody (mogamulizumab) therapies in a patient with adult t cell leukemia/lymphoma:insight into auto inflammatory diseases. Intern Med. 2016;55(10):1345–1349.
22. Tanaka H, Fujiwara H, Ochi F, et al. Development of engineered T cells expressing a chimeric CD16-CD3ζ receptor to improve the clinical efficacy of mogamulizumab therapy against adult T cell leukemia. Clin Cancer Res. 2016 [cited 2016 Apr18];22:4405–4416.
23. Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010 Jun 3;115(22):4337–4343.
24. Tsukasaki K, Utsunomiya A, Fukuda H, et al. Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458–5464.
25. Subramaniam J, Whiteside G, Mckeage K. et al. Mogamulizumab:first global approval. Drugs. 2012;72(9):1293–1298.
26. Mogamulizumab. ClinicalTrials.gov. U.S. Bethesda (MD):National Library of Medicine (US); 2016. Available from:https://clinicaltrials.gov/ct2/results?term=mogamulizumab